Literature DB >> 35481960

Retraction: Gemcitabine aggravates miR-199a-5p-mediated breast cancer cell apoptosis by promoting VEGFA downregulation via inactivating the AKT signaling pathway.

Laura Fisher1.   

Abstract

[This retracts the article DOI: 10.1039/C9RA00016J.]. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 35481960      PMCID: PMC9031743          DOI: 10.1039/d1ra90114a

Source DB:  PubMed          Journal:  RSC Adv        ISSN: 2046-2069            Impact factor:   3.361


The Royal Society of Chemistry hereby wholly retracts this RSC Advances article due to concerns with the reliability of the data. The images in the article, and the raw data provided by the authors, were screened by an image integrity expert. All the western blots in the article contain very unusually regular-shaped bands. The raw data provided for the western blot images does not appear to be genuine. There are traces of cloning in the background of the raw data for multiple panels, including Fig. 3 (Bax-MCF-7 and Cle-caspase-3-MCF-7) and Fig. 4 (VEGFA-MCF-7), indicating that the raw data was manipulated. In addition, for a number of panels, the area immediately around the bands in the raw data does not exactly match the published images. The bands in the figure panels also appear closer to each other than in the raw data. The raw data provided by the authors, therefore, cannot be used to validate the published data. Given the significance of the concerns about the validity of both the data in the article and the raw data provided by the authors, the findings in this paper are not reliable. The authors agree to the retraction. Signed: Laura Fisher, Executive Editor, RSC Advances Date: 9th April 2021
  1 in total

1.  Effects of Gemcitabine and Oxaliplatin Combined with Apatinib on Immune Function and Levels of SIL-2R and sicAM-1 in Patients with Gallbladder Cancer.

Authors:  Linlin Qu; Kun Li; Kui Liu; Weiyu Hu
Journal:  Comput Intell Neurosci       Date:  2022-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.